Samsung Biologics is expanding its bioconjugation portfolio beyond traditional antibody-drug conjugates (ADCs) to include emerging non-cytotoxic formats such as antibody-oligonucleotide conjugates (AOCs) and antibody-siRNA conjugates (ARCs), supported by the co-location of its GMP manufacturing facilities and dedicated ADC manufacturing facility.
In this on-demand webinar, Enseo Ency Lee, Ph.D., Director of New Modality at Samsung Biologics, provides an update on the company's expanding bioconjugation capabilities and discusses how its integrated end-to-end services support commercial-scale manufacturing for next-generation therapeutics.
Key highlights include:
Our newly established ADC-dedicated manufacturing facility
Expanded bioconjugation capabilities beyond ADCs
How our co-located GMP manufacturing network enables seamless end-to-end support from development through commercial manufacturing
Samsung Biologics is expanding its bioconjugation portfolio beyond traditional antibody-drug conjugates (ADCs) to include emerging non-cytotoxic formats such as antibody-oligonucleotide conjugates (AOCs) and antibody-siRNA conjugates (ARCs), supported by the co-location of its GMP manufacturing facilities and dedicated ADC manufacturing facility.
In this on-demand webinar, Enseo Ency Lee, Ph.D., Director of New Modality at Samsung Biologics, provides an update on the company's expanding bioconjugation capabilities and discusses how its integrated end-to-end services support commercial-scale manufacturing for next-generation therapeutics.
Key highlights include:
- Our newly established ADC-dedicated manufacturing facility
- Expanded bioconjugation capabilities beyond ADCs
- How our co-located GMP manufacturing network enables seamless end-to-end support from development through commercial manufacturing
Related Content